Hans-Wilhelm Schwaeble

This inventor holds 19 USPTO granted patents and 56 published patent applications, plus 18 CIPO patents and 15 EPO patents. Top assignees: University of Leicester, Omeros Corporation. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Wilhelm Schwaeble. Retrieved from https://idiyas.com/inventor/hans-wilhelm-schwaeble

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 56)

% Patents Active = 100.0

CIPO Patents = 18 (Patent Applications = 10)

EPO Patents = 15 (Patent Applications = 38)

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 132(Granted Patents)

Location History:

Mountsorrel, GB (2011 - 2024)
Cambridge, GB (2024)

Company Filing History:

19 out of 84

University of Leicester

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12005117 - Methods for inhibiting fibrosis in a subject in need thereof (2024-06-11),

2. 11981749 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-05-14),

3. 11981748 - Methods for inhibiting angiogenesis in a subject in need thereof (2024-05-14),

4. 11896621 - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant (2024-02-13),

5. 11884742 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-01-30),

6. 11525011 - Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome (2022-12-13),

7. 11013772 - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant (2021-05-25),

8. 10870708 - Methods for inhibiting angiogenesis in a subject in need thereof (2020-12-22),

9. 10736960 - Methods for inhibiting fibrosis in a subject in need thereof (2020-08-11),

10. 10660317 - Genetically modified non-human mammals and cells (2020-05-26),

11. 10626184 - Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer (2020-04-21),

12. 10202465 - Methods for treating conditions associated with MASP-2 dependent complement activation (2019-02-12),

13. 10059776 - Methods for treating conditions associated with MASP-2 dependent complement activation (2018-08-28),

14. 9644035 - Methods for treating conditions associated with MASP-2 dependent complement activation (2017-05-09),

15. 8951522 - Methods for treating conditions associated with MASP-2 dependent complement activation (2015-02-10),

Title: Innovator Spotlight: Hans-Wilhelm Schwaeble - Pioneering Researcher in Fibrosis Treatment

Introduction:

Hans-Wilhelm Schwaeble is a distinguished inventor based in Mountsorrel, GB, renowned for his groundbreaking research in developing methods to treat and inhibit fibrosis in patients. With an impressive portfolio of 19 patents to his name, Schwaeble's innovative work is reshaping the landscape of medical treatments for conditions related to fibrosis and inflammation.

Latest Patents:

Schwaeble's latest patents showcase his commitment to advancing medical science and improving patient outcomes. One notable invention focuses on methods for inhibiting fibrosis in mammalian subjects, particularly those suffering from renal fibrosis. By administering MASP-2 inhibitory agents, Schwaeble's groundbreaking methods aim to alleviate the effects of complement activation and reduce proteinuria in patients with renal diseases.

Another recent patent by Schwaeble addresses conditions associated with MASP-2 dependent complement activation, specifically targeting patients with TMA linked to hematopoietic stem cell transplants. Through the administration of MASP-2 inhibitory agents, Schwaeble's innovative approach offers hope for individuals grappling with the effects of complement activation-related disorders.

Career Highlights:

Throughout his illustrious career, Hans-Wilhelm Schwaeble has made significant contributions to the field of medical research. Having worked with reputable institutions such as the University of Leicester and Omeros Corporation, Schwaeble has garnered a reputation as a visionary in the realm of fibrosis treatment. His relentless pursuit of scientific excellence has led to numerous breakthroughs that have the potential to transform patient care and improve quality of life.

Collaborations:

In his pursuit of innovation, Schwaeble has collaborated with esteemed professionals in the industry, including Gregory A Demopulos and Thomas Dudler. Through these partnerships, Schwaeble has been able to harness diverse perspectives and expertise, fostering a collaborative environment that nurtures creativity and accelerates the pace of discovery.

Conclusion:

In conclusion, Hans-Wilhelm Schwaeble stands as a trailblazer in the field of medical research, with a remarkable track record of patenting innovative methods to address fibrosis-related conditions. His relentless pursuit of scientific excellence, coupled with his collaborative spirit, underscores Schwaeble's commitment to pushing the boundaries of medical innovation and revolutionizing patient care. We eagerly anticipate the future breakthroughs that will undoubtedly stem from Schwaeble's pioneering work in the realm of fibrosis treatment.

Profile summary based on public USPTO records.